TITLE:
Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

CONDITION:
Diabetes Mellitus, Type 2

INTERVENTION:
vildagliptin

SUMMARY:

      The purpose of this study is to assess the safety and effectiveness of vildagliptin, an
      unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in
      people with type 2 diabetes who have not previously been treated with drug therapy to lower
      their blood sugar.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 80 Years
Criteria:

        Inclusion Criteria:

          -  Blood glucose criteria must be met

          -  Not currently on drug therapy for type 2 diabetes

          -  Body mass index (BMI) in the range 22-45

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Type 1 diabetes

          -  Evidence of serious diabetic complications

          -  Evidence of serious cardiovascular conditions

          -  Laboratory value abnormalities as defined by the protocol

          -  Other protocol-defined exclusion criteria may apply
      
